mail
editor@ajptr.com
whatsapp
9409046853
logo

American Journal of PharmTech Research

Published

Prodrugs- A Regulatory Prospective

Published in December 2022 Issue 6 (Vol. 12, Issue 6, 2022)

Prodrugs- A Regulatory Prospective - Issue cover

Abstract

Prodrugs are unique due to special features in contrast to drugs. The primary goal of prodrug design is to conceal harmful drug features, such as low solubility in water or lipid membranes, low target selectivity, chemical instability, undesirable taste, irritation or pain after local administration, presystemic metabolism and toxicity. The prodrug approach emphasizes on the improvements accomplished by developing the prodrug as compared to the free or parent drug. By determining market exclusivity, assessing viability and finding an optimum development pathway such as that offered by the 505(b)(2) process, developers may find that prodrugs present an ideal alternative to new drug development. There is no guidance on the acceptable development path for prodrugs. A clear understanding of what the classification means in terms of the studies required to support clinical development is needed.

Download Article

PDF

Best for printing and citation

File size: 0.0 MB
Format: PDF

Download Article

PDF

Best for printing and citation

File size: 0.0 MB
Format: PDF

Article Information

Article ID:
AJPTR126004
Paper ID:
AJPTR-01-002164
Published Date:
2022-12-01

Article Impact

Views:4,618
Downloads:1,991
scite_
PlumX Metrics Badge

How to Cite

Rana & Rahi (2022). Prodrugs- A Regulatory Prospective. American Journal of PharmTech Research, 12(6), xx-xx. DOI:https://doi.org/10.5281/zenodo.7407634

Article Actions

Whatsapp